Who are Dexmedetomidine and Fentanyl's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-and-fentanyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexmedetomidine and Fentanyl — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine and Fentanyl (Dexmedetomidine and Fentanyl) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-analgesic combination (alpha-2 agonist + opioid). Area: Anesthesia and Perioperative Medicine.

phase 3 Sedative-analgesic combination (alpha-2 agonist + opioid) Alpha-2 adrenergic receptor (dexmedetomidine); mu-opioid receptor (fentanyl) Anesthesia and Perioperative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine and Fentanyl (Dexmedetomidine and Fentanyl) — University of Jordan. Dexmedetomidine and fentanyl work synergistically as a sedative-analgesic combination, with dexmedetomidine acting as an alpha-2 adrenergic agonist and fentanyl as an opioid mu-receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexmedetomidine and Fentanyl TARGET	Dexmedetomidine and Fentanyl	University of Jordan	phase 3	Sedative-analgesic combination (alpha-2 agonist + opioid)	Alpha-2 adrenergic receptor (dexmedetomidine); mu-opioid receptor (fentanyl)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-analgesic combination (alpha-2 agonist + opioid) class)

University of Jordan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine and Fentanyl — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-and-fentanyl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab